New! Sign up for our free email newsletter.
Science News
from research organizations

New biomarker in the blood may help predict Alzheimer’s disease

Date:
July 18, 2012
Source:
American Academy of Neurology (AAN)
Summary:
Higher levels of a certain fat in the blood called ceramides may increase a person’s risk of developing Alzheimer’s disease, according to a new study.
Share:
FULL STORY

Higher levels of a certain fat in the blood called ceramides may increase a person's risk of developing Alzheimer's disease, according to a study published in the July 18, 2012, online issue of Neurology®, the medical journal of the American Academy of Neurology.

"Our study identifies this biomarker as a potential new target for treating or preventing Alzheimer's disease," said study author Michelle M. Mielke, PhD, an epidemiologist with the Mayo Clinic in Rochester, Minn. Mielke was with Johns Hopkins University at the time of the research.

For the study, 99 women between the ages of 70 and 79 and free of dementia in the Women's Health and Aging Study II had their blood tested for levels of serum ceramides, a fatty compound found throughout the body that is associated with inflammation and cell death. The participants were placed into three groups: high, middle and low levels of ceramides. They were then followed for up to nine years. Of the 99 participants, 27 developed dementia and 18 of those were diagnosed with probable Alzheimer's disease.

The study found that women who had the highest levels of the biomarker were 10 times more likely to develop Alzheimer's disease than women with the lowest levels. Those with middle levels of the biomarker were nearly eight times more likely to develop the disease than those with the lowest levels.

"These findings are important because identifying an accurate biomarker for early Alzheimer's that requires little cost and inconvenience to a patient could help change our focus from treating the disease to preventing or delaying it," said Valory Pavlik, PhD, with the Alzheimer's Disease and Memory Disorders Center of Baylor College of Medicine in Houston and a member of the American Academy of Neurology, in an accompanying editorial.

According to Pavlik, "While a larger, more diverse study is needed to confirm these findings, projections that the global prevalence of Alzheimer's disease will double every 20 years for the foreseeable future have certainly increased the sense of urgency among researchers and health care agencies to identify more effective screening, prevention and treatment strategies."

The study was supported by the National Institute on Aging, the National Institute of Neurological Disorders and Stroke and the Johns Hopkins Older Americans Independence Center.


Story Source:

Materials provided by American Academy of Neurology (AAN). Note: Content may be edited for style and length.


Journal Reference:

  1. Valory Pavlik. Serum ceramides—A new biomarker for preclinical AD? Neurology, July 18, 2012 DOI: 10.1212/WNL.0b013e318264e3e2

Cite This Page:

American Academy of Neurology (AAN). "New biomarker in the blood may help predict Alzheimer’s disease." ScienceDaily. ScienceDaily, 18 July 2012. <www.sciencedaily.com/releases/2012/07/120718164559.htm>.
American Academy of Neurology (AAN). (2012, July 18). New biomarker in the blood may help predict Alzheimer’s disease. ScienceDaily. Retrieved March 18, 2024 from www.sciencedaily.com/releases/2012/07/120718164559.htm
American Academy of Neurology (AAN). "New biomarker in the blood may help predict Alzheimer’s disease." ScienceDaily. www.sciencedaily.com/releases/2012/07/120718164559.htm (accessed March 18, 2024).

Explore More

from ScienceDaily

RELATED STORIES